Company
Frazier Life Sciences
Investments
| Company | Round | Date | Lead |
|---|---|---|---|
| Sidewinder Therapeutics | Series B | 2026-04-09 | Lead |
| AirNexis Therapeutics | Series A | 2026-01-12 | Lead |
| Parabilis Medicines | Series F | 2026-01-08 | |
| Aspen Neuroscience | Series C | 2025-11-20 | Lead |
| Braveheart Bio | Series A | 2025-11-05 | |
| Star Therapeutics | Series D | 2025-10-01 | |
| Attovia Therapeutics | Series C | 2025-04-16 | Lead |
| Halda Therapeutics | Series B | 2024-08-12 | |
| Scorpion Therapeutics | Series C Financing | 2024-07-16 | Lead |
| Attovia Therapeutics | series b | 2024-05-10 | |
| Bluejay Therapeutics | series c | 2024-05-09 | Lead |
| Enlaza Therapeutics | Series A Funding | 2024-04-30 | |
| Diagonal Therapeutics | Financing | 2024-04-04 | |
| Sudo Biosciences | Series B | 2024-02-13 | |
| Lassen Therapeutics | Series B | 2023-12-20 | Lead |
| Sudo Biosciences | Series B | 2023-12-20 | |
| Carmot Therapeutics | Series E Equity Financing | 2023-05-31 | |
| Enlaza Therapeutics | Seed | 2022-12-19 | |
| Sudo Biosciences | Series A | 2022-09-29 | Lead |